fbpx
X

Ongoing Projects

The active research projects are available for viewing on the clinique ovo website, in the waiting room’s television screens and on the clinicaltrials.gov website.

You are free to communicate with the research team for any questions regarding the project that might be of interest to you.

  • Académie

     

  • Request for information (Accueil)

  • Discover the ovo clinic

    Discover the ovo clinic

  • Contact us

    Contact us

    clinique ovo montreal

    All services offered
    8000, boul. Décarie,
    Montreal Qc H4P 2S4

    ovo fertility
    office 100 & 200
    Business hours:
    Monday to Friday 7:30am to 4pm
    Saturday, Sunday and holidays: 8am to 2:30pm
    Call center schedule:
    Monday to Friday 7:30am to 5pm
    Saturday and Sunday: 8am to 12pm
    fertilite@cliniqueovo.com
    ovo elle
    bureau 600
    Monday to Friday 8am to 4pm
    elle@cliniqueovo.com
    ovo cryo
    Monday to Wed. 8am to 5pm
    Thursday 8am to 6pm
    Friday 8am to 5pm
    Saturday 9am to 3pm
    Appointments :
    Monday to Friday 9am to 3pm
    Thursday 9am to 4pm
    Saturday 9am to 2:30pm
    cryo@cliniqueovo.com
    ovo biosurance
    office 600
    Monday to Friday 8am to 4pm
    biosurance@cliniqueovo.com
    ovo labo
    office 600
    Monday to Friday 8am to 4pm
    labo@cliniqueovo.com
    ovo prenatal
    office 600
    Monday to Friday 8am to 4pm
    prenatal@cliniqueovo.com
    ovo r&d
    office 600
    Monday to Friday 7:15am to 5pm
    r-d@cliniqueovo.com

    clinique ovo rive-sud

    3141, boul. Taschereau,
    Greenfield Park Qc J4V 2H2

    ovo fertility – some services offered
    office 410
    Business hours:
    Monday to Friday 7:30am to 4pm
    Call center schedule:
    Monday to Friday 7:30am to 5pm
    Saturday and Sunday: 8am to 12pm
    fertilite@cliniqueovo.com
    ovo prenatal – some services offered
    office 420
    Monday to Friday 8 am to 4 pm
    prenatal@cliniqueovo.com
    ovo labo – some services offered
    office 420
    Monday to Friday 8am to 4pm
    labo@cliniqueovo.com

    clinique ovo quebec

    ovo prenatal – some services offered
    2600 Boul. Laurier, suite 295,
    Quebec Qc G1V 4T3

     

    Monday to Friday 8am to 4pm
    prenatal@cliniqueovo.com

    clinique ovo rive-nord

    ovo prenatal – Prenatal screening
    1000 Montée des Pionniers,
    Terrebonne QC J6V 1S8

     

    Monday to Thursday 9am to 3pm
    prenatal@cliniqueovo.com

    clinique Echo-medic

    Ovo prenatal – some services

    Laval
    1575, boul. de l’Avenir, suite 110,
    Laval Qc H7S 2N5
    t. 1.877.664.3246
    Monday to Thursday 7:30am to 4:30pm
    Friday 7:30am to 3pm
    Boisbriand
    20865, chemin de la Côte Nord, suite 201
    Boisbriand Qc J7E 4H5
    t. 1.877.664.3246
    Monday to Thursday 8 am to 4pm
    Friday 8am to 3pm

    Soins de santé du nord

    Ovo prenatal – some services

    Mont-Laurier
    742 rue de la Madone
    Mont-Laurier Qc J9L 1S9
    t. 819.440.2024
    On appointment
    Montreal and South-Shore: t. 514.798.2000
    Quebec: t. 418.425.0128
    f. 514.798.2001

  • Announce your Day 1

  • Make an appointment

  • Online payment

    Online payment

IN VITRO FERTILIZATION

AdhesioRT
This project allows you to personalize the day of your frozen embryo transfer.

Principal Investigator: Dr Jacques Kadoch

 

Summary: The objective of the project is to compare standard frozen embryo transfer (substituted TEC) with sub TEC using the adhesioRT test to determine when the endometrium is receptive to receive the frozen embryo.
* Costs associated with adhesioRT test procedures will be covered.

 

Number of participants: 120

 

Learn more about adhesioRT : adhesioRT page link

 

Project Coordinator: Sophie Leblanc – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 617 or at R-D@cliniqueovo.com

 



GROWTH HORMONE (recruitment completed)
Adjuvant growth hormone therapy in in-vitro fertilization: a randomized controlled trial

Principal Investigator : Dr Jacques Kadoch

 

Sponsor : ovo fertility

 

Partnership : EMD Serono Canada

 

Summary: In an In Vitro Fertilization (IVF) cycle, ovarian stimulation drugs (gonadotrophins) are usually taken to stimulate the ovaries to produce more than one egg. IVF protocols are constantly under review in order to improve the recruitment of the follicles, which contains the eggs, while minimizing the doses of gonadotropins required with the ultimate aim of increasing the live birth rate. The addition of growth hormone, which is a biological hormone that can be synthetically produced, as a supplement to gonadotrophins in an IVF cycle, has been suggested as a way in which IVF pregnancy rates may be increased.
The purpose of this study is to determine the effectiveness of using growth hormone therapy as a supplement during her treatment

 

Number of participants : 528, recruitment will be done only at the clinique ovo.

 

Project Coordinator: Michelle Roberge – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 755 or at R-D@cliniqueovo.com.

 

ClinicalTrials.gov ID : NCT01715324


GAVI (recruitment completed)
Evaluation of an automated vitrification system in comparison with the traditional manual vitrification technique by verifying the impact of the user on the survival rate and on the pregnancy rate.

Principal Investigator: Simon Phillips, Msc, director of the embryology department at clinique ovo.

 

Sponsor: ovo fertility

 

In collaboration with EMD Serono

 

Summary : GAVI, the automated vitrification system (freezing of the embryos) developped by an Australian team and commercialized in Canada since 2016, is being studied to confirm its equivalence with the manual vitrification technique done by the embryologists. Results from previous studies have shown that GAVI’s automated vitrification system is comparable to the CRYOTOP manual technique used at clinique ovo. With this research project, clinique ovo wants to verify if there is an added advantage to using GAVI’s automated vitrification system. Since this system is automated, we believe it may better the results for the cryopreservation (freezing) of embryos.

 

Number of participants needed: 168

 

Number of recruiting sites: 01, clinique ovo

 

Project Coordinator: Lindsay Joseph – To learn more about this research project, please contact (514) 798-2000 ext. 756 or at
R-D@cliniqueovo.com.

CHRONIC ENDOMETRITIS (recruitment completed)
Chronic endometritis in patients with repetitive miscarriages or repeated implantation failures following IVF treatments.

Principal Investigator : Dr. Joanne Benoît, MD

 

Sponsor : ovo fertility

 

Summary : Chronic endometritis is a persistent inflammation of the endometrium. Clinically, it presents a few or no symptoms. It is sometimes characterized by vaginal bleeding, chronic pelvic pain, discomfort during intercourse and persistent white vaginal discharge. Absence or presence of chronic endometritis is detected by histological analysis of the endometrial biopsy.
Few studies have demonstrated that endometritis may have an impact on the uterine implantation of the embryo and hence, explain repetitive miscarriages and repeated implantation failures.
The aim of this study is to evaluate the frequency of chronic endometritis in patients presenting repetitive miscarriages and repeated implantation failures during in vitro fertilization treatments.

 

Number of participants: 200 women

 

Project Coordinator : Sophie Leblanc – For further information on this study, contact the person in charge of the project at (514) 798-2000 ext 617 or at R-D@cliniqueovo.com.

 

INSEMINATION

IUI scratching

Randomized controlled trial on the impact of uterine scratching prior to intrauterine insemination in unexplained infertility.

Principal Investigator : Dr Louise Lapensée, MD

 

Sponsor : ovo fertility

 

Summary : Among the possible medical care in assisted reproduction for couples affected by unexplained infertility, several methods can be considered, including initially increasing the number of oocytes by ovarian stimulation and synchronizing intrauterine insemination (IUI) of sperm during ovulation. Most of the time, this is ovarian stimulation with clomiphene citrate, tamoxifen, letrozole and / or gonadotropin, possibly followed by IUI.
However, an emerging medical practice, endometrial scratching, would benefit couples with unexplained infertility. This corresponds to the realization of a microtrauma of the endometrium using a Cornier pipelle. This procedure is recognized in IVF for women with unexplained repeated implantation failures because it increases pregnancy rates.

 

Number of participants: 197 patients per cohort for a total of 394, unicentric recruitment at the ovo clinic.

 

Project Coordinator : Michelle Roberge – For more information on this research project, you can contact the person in charge of the project at (514) 798-2000 ext 602 or at R-D@cliniqueovo.com.

 

PITS

Effect of personalized dosages of Rekovelle on the number of mature follicles reached in intra-uterine insemination

Principal Investigator : Dr Jacques Kadoch, MD

 

Sponsor : ovo fertility

 

Collaboration with: Ferring pharmaceuticals, subsidy holder

 

Summary : The aim of the research project is to evaluate the dose response of Rekovelle when we use a personalized dose during 3 intrauterine inseminations. We will also assess the adjustment of these doses of Rekovelle after each insemination. Rekovelle is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line now approved by Health Canada.
Anyone participating in the research project will receive a prescription for Rekovelle. The prescribed dose of Rekovelle will be determined by the weight as well as the AMH strength present in the medical file. AMH, the antimüllerian hormone, is a marker of ovarian reserve and an indicator of female reproductive potential.

 

Number of participants: 110 patients

 

Project Coordinator : Lindsay Joseph – For more information on this research project, you can contact the person in charge of the project at (514) 798-2000 ext 756 or at R-D@cliniqueovo.com.

 

FIBROME

None.

 

 

Subjects
in the page

 

 

 

Ask for information

ENDOMETRIOSIS

Schumann-Endometriosis
A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus placebo and Elagolix 150 mg in women with symptomatic endometriosis.

Principal Investigator : Dr François Bissonnette

 

Sponsor: Bayer

 

Number of participants : 5.

 

Project Coordinator: Lindsay Joseph – For more information on this research project, you can contact the person in charge of the project at (514) 798-2000 ext 756 or at R-D@cliniqueovo.com.


 

 

STEM CELLS

None.

PRENATAL SCREENING

None.

 

 

MEN’S HEALTH

None.

 

 

DIVERS

MOM (recruitment completed)
A randomised double blind placebo controlled study evaluating the effect of probiotics for an ongoing healthy pregnancy and the newborn.

Principal Investigator: Dr. Jacques Kadoch

 

Sponsor: Lallemand Health Solutions

 

Summary : During pregnancy, the women’s body experiences many biologic and physiologic changes. Modifications are also observed within the vaginal and intestinal microbiotas. Unbalanced microbiotas may increase risks of pregnancy complications affecting the mother or new born due to some related infections. The current available treatments for these types of urogenital infections may not always work to prevent recurring infections and often they tend to be recurrent, develop resistance and may have some secondary effects and counter-indications.
Many researches have demonstrated the advantages to intake probiotics for the modulation of the immune response. The probiotics contribute in the maintenance of healthy microbiotas by strengthening the inflammatory and immune response as well as the maintenance of a balanced PH level.
Other studies are essential to observe the potential positive effects on pregnant women. The intake of probiotics could benefit the health of pregnant women by reducing the numbers of viral infections and digestive/intestinal troubles. The intake of probiotic during pregnancy and breastfeeding could also demonstrate positive effects on the mother and newborn. This could lower the risk of mastitis, maintain the healthy digestive system development, protecting against the pathogenic agent and regulating the immune response.
The objective of this study is to evaluate the effects of the intake of probiotics during pregnancy and the first few weeks after birth. This objective will be evaluated with the documentation of the number of viral, fungal and bacterial infections, maintenance of a healthy pregnancy and the beneficial impact in pregnant women, their newborn and during breastfeeding.
Number of participants required: 240 pregnant women between 26 and 28 week of pregnancy and being followed by an obstetrician at clinique ovo.

 

Project coordinator : Michelle Roberge

 

For more information on this research project, you may communicate with the project coordinators at 514-798-2000 extension 755 or by email at : R-D@cliniqueovo.com

Our partnerships

 

 

 

Patient Feedback

« Pour moi et mon conjoint la participation à un projet de recherche fut une expérience positive. Notre implication au projet de recherche nous a donné une chance supplémentaire de réaliser notre rêve d’avoir un bébé. Nous avons pu par notre implication faire évoluer la science et faire bénéficier dans le futur d’autres couples. Nous avons eu un suivi personnalisé, un accès privilégié à une infirmière dévouée à notre dossier. »

Patiente ovo r&d

Regulations

Future Projects